BD Launches First Central Venous Catheter Insertion System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BDX?
Source: PRnewswire
- Product Innovation: BD's launch of the CentroVena One™ Insertion System introduces the first all-in-one central venous catheter device to the market, designed to simplify central line placement for clinicians and enhance patient safety in acute care settings.
- Process Optimization: By consolidating essential components such as the introducer needle, syringe, guidewire, and catheter, the system reduces procedural steps, lowers the risk of complications, and enables clinicians to deliver faster care in high-pressure environments.
- Pilot Feedback: As one of the first health systems to pilot the CentroVena One™, UNC Health Blue Ridge reported that the system effectively reduced opportunities for errors and breaches of sterile fields, thereby improving care quality and patient safety in real-world applications.
- Market Expansion Strategy: The commercial launch of CentroVena One™ marks BD's entry into the acute CVC market, further expanding its vascular access portfolio and demonstrating a commitment to reducing the risk of vascular access-related complications while improving clinical and economic outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 150.220
Low
157.00
Averages
192.64
High
232.00
Current: 150.220
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BD Launches First Central Venous Catheter Insertion System
- Product Innovation: BD's launch of the CentroVena One™ Insertion System introduces the first all-in-one central venous catheter device to the market, designed to simplify central line placement for clinicians and enhance patient safety in acute care settings.
- Process Optimization: By consolidating essential components such as the introducer needle, syringe, guidewire, and catheter, the system reduces procedural steps, lowers the risk of complications, and enables clinicians to deliver faster care in high-pressure environments.
- Pilot Feedback: As one of the first health systems to pilot the CentroVena One™, UNC Health Blue Ridge reported that the system effectively reduced opportunities for errors and breaches of sterile fields, thereby improving care quality and patient safety in real-world applications.
- Market Expansion Strategy: The commercial launch of CentroVena One™ marks BD's entry into the acute CVC market, further expanding its vascular access portfolio and demonstrating a commitment to reducing the risk of vascular access-related complications while improving clinical and economic outcomes.
See More
BD Declares Quarterly Dividend of $1.05 per Share
- Quarterly Dividend Announcement: BD has declared a quarterly dividend of $1.05 per share, payable on June 30, 2026, to shareholders of record on June 9, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Annual Dividend Rate: The indicated annual dividend rate stands at $4.20 per share, reflecting the company's strong cash flow and profitability, which enhances investor confidence in BD's financial stability.
- Global Medical Technology Leader: BD is one of the world's largest pure-play medical technology companies, dedicated to advancing medical essentials, connected care, and biopharma systems, thereby improving the quality of healthcare globally.
- Employee and Product Delivery: With over 60,000 employees worldwide, BD delivers billions of products annually, significantly impacting global healthcare, underscoring the company's vital role and influence in the industry.
See More
BD to Present at Bank of America Health Care Conference
- Conference Details: BD (Becton, Dickinson and Company) will present at the Bank of America Securities Health Care Conference on May 12, 2026, at 11:40 AM ET, aiming to enhance its visibility and credibility among investors in the medical technology sector.
- Live Webcast: The presentation will be accessible via BD's investor relations website, allowing global investors to stay informed about the company's strategic direction and business developments, with a replay available post-event to ensure widespread information dissemination.
- Company Overview: BD is one of the world's largest pure-play medical technology companies, committed to advancing health through innovation, employing over 60,000 people and delivering billions of products annually that positively impact global healthcare.
- Customer Collaboration: By closely collaborating with customers, BD aims to enhance clinical efficiency, reduce costs, improve safety, and expand access to healthcare, thereby securing a significant position in the global healthcare market.
See More
Positive Outlook for Medical Supply Industry
- Industry Growth Drivers: The global medical supplies market is projected to reach $163.5 billion by 2027, with a CAGR of 3.4%, indicating sustained growth driven by an aging population and innovation, benefiting companies like Cardinal Health and Becton, Dickinson.
- Technological Innovations: The healthcare sector is transitioning to digital-first operating models with AI integration, where automation tools enhance efficiency and reduce administrative burdens, thereby supporting predictive care delivery and improving patient engagement.
- Shifting Market Demand: The U.S. dental equipment market is structurally supported by demographic aging and rising disease prevalence, with the 65+ population driving increased procedure volumes and equipment utilization, reflecting a strong demand for high-quality healthcare services.
- Competition and Challenges: Despite the optimistic outlook, the industry faces challenges from procurement pressures in China, inflation, and regulatory uncertainties, necessitating companies to diversify sourcing and optimize supply chains to maintain competitive positioning.
See More
Becton, Dickinson's Investment Potential
- Healthcare Spending Surge: According to the Peterson-KFF Health System Tracker, per capita healthcare spending in the U.S. has risen from $353 in 1970 to $15,474 in 2024, indicating a robust growth potential in the healthcare sector that attracts investor interest.
- Stable Revenue Sources: Becton, Dickinson derives much of its revenue from essential products like syringes and blood collection tubes, which are always in demand in the healthcare industry, ensuring a steady income stream and reducing investment risk.
- Growing Dividend Returns: The company boasts a dividend yield of 2.7%, with quarterly dividends increasing from $0.83 in 2021 to $1.05 by 2026, reflecting a 5% average annual growth rate, demonstrating a strong commitment to shareholder returns.
- Stock Buyback Program: Becton, Dickinson has repurchased $250 million worth of shares in 2026 and authorized an additional 10 million shares for buyback, indicating management's belief that the stock is undervalued and their dedication to enhancing shareholder value.
See More
Investment Opportunities in Becton, PepsiCo, and Procter & Gamble
- Becton’s Recovery Outlook: Following a spinoff, Becton, Dickinson's shares trade at approximately 12 times forward earnings, significantly lower than peers at 15 times, with analysts forecasting a rebound in earnings by 2027, which could drive stock price recovery and improve investor sentiment.
- PepsiCo's Undervalued Position: Despite facing potential impacts from GLP-1 weight-loss drugs and inflationary pressures, PepsiCo's stock currently trades at just 18 times forward earnings, compared to Coca-Cola's 23.5 times, indicating strong return potential while offering a 3.65% dividend yield.
- Procter & Gamble’s Steady Investment: With a 70-year track record of consecutive dividend growth, Procter & Gamble's stock trades near 20 times forward earnings, yet its average 6% annual dividend growth makes it an ideal choice for long-term wealth accumulation, especially during economic fluctuations.
- Market Opportunities and Risks: While the broader market may be recovering, high-quality dividend stocks still carry the risk of value traps, necessitating careful screening for companies with competitive advantages to avoid potential investment losses.
See More
BD Launches First Central Venous Catheter Insertion System
- Product Innovation: BD's launch of the CentroVena One™ Insertion System introduces the first all-in-one central venous catheter device to the market, designed to simplify central line placement for clinicians and enhance patient safety in acute care settings.
- Process Optimization: By consolidating essential components such as the introducer needle, syringe, guidewire, and catheter, the system reduces procedural steps, lowers the risk of complications, and enables clinicians to deliver faster care in high-pressure environments.
- Pilot Feedback: As one of the first health systems to pilot the CentroVena One™, UNC Health Blue Ridge reported that the system effectively reduced opportunities for errors and breaches of sterile fields, thereby improving care quality and patient safety in real-world applications.
- Market Expansion Strategy: The commercial launch of CentroVena One™ marks BD's entry into the acute CVC market, further expanding its vascular access portfolio and demonstrating a commitment to reducing the risk of vascular access-related complications while improving clinical and economic outcomes.
See More
BD Declares Quarterly Dividend of $1.05 per Share
- Quarterly Dividend Announcement: BD has declared a quarterly dividend of $1.05 per share, payable on June 30, 2026, to shareholders of record on June 9, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Annual Dividend Rate: The indicated annual dividend rate stands at $4.20 per share, reflecting the company's strong cash flow and profitability, which enhances investor confidence in BD's financial stability.
- Global Medical Technology Leader: BD is one of the world's largest pure-play medical technology companies, dedicated to advancing medical essentials, connected care, and biopharma systems, thereby improving the quality of healthcare globally.
- Employee and Product Delivery: With over 60,000 employees worldwide, BD delivers billions of products annually, significantly impacting global healthcare, underscoring the company's vital role and influence in the industry.
See More
BD to Present at Bank of America Health Care Conference
- Conference Details: BD (Becton, Dickinson and Company) will present at the Bank of America Securities Health Care Conference on May 12, 2026, at 11:40 AM ET, aiming to enhance its visibility and credibility among investors in the medical technology sector.
- Live Webcast: The presentation will be accessible via BD's investor relations website, allowing global investors to stay informed about the company's strategic direction and business developments, with a replay available post-event to ensure widespread information dissemination.
- Company Overview: BD is one of the world's largest pure-play medical technology companies, committed to advancing health through innovation, employing over 60,000 people and delivering billions of products annually that positively impact global healthcare.
- Customer Collaboration: By closely collaborating with customers, BD aims to enhance clinical efficiency, reduce costs, improve safety, and expand access to healthcare, thereby securing a significant position in the global healthcare market.
See More
Positive Outlook for Medical Supply Industry
- Industry Growth Drivers: The global medical supplies market is projected to reach $163.5 billion by 2027, with a CAGR of 3.4%, indicating sustained growth driven by an aging population and innovation, benefiting companies like Cardinal Health and Becton, Dickinson.
- Technological Innovations: The healthcare sector is transitioning to digital-first operating models with AI integration, where automation tools enhance efficiency and reduce administrative burdens, thereby supporting predictive care delivery and improving patient engagement.
- Shifting Market Demand: The U.S. dental equipment market is structurally supported by demographic aging and rising disease prevalence, with the 65+ population driving increased procedure volumes and equipment utilization, reflecting a strong demand for high-quality healthcare services.
- Competition and Challenges: Despite the optimistic outlook, the industry faces challenges from procurement pressures in China, inflation, and regulatory uncertainties, necessitating companies to diversify sourcing and optimize supply chains to maintain competitive positioning.
See More
Becton, Dickinson's Investment Potential
- Healthcare Spending Surge: According to the Peterson-KFF Health System Tracker, per capita healthcare spending in the U.S. has risen from $353 in 1970 to $15,474 in 2024, indicating a robust growth potential in the healthcare sector that attracts investor interest.
- Stable Revenue Sources: Becton, Dickinson derives much of its revenue from essential products like syringes and blood collection tubes, which are always in demand in the healthcare industry, ensuring a steady income stream and reducing investment risk.
- Growing Dividend Returns: The company boasts a dividend yield of 2.7%, with quarterly dividends increasing from $0.83 in 2021 to $1.05 by 2026, reflecting a 5% average annual growth rate, demonstrating a strong commitment to shareholder returns.
- Stock Buyback Program: Becton, Dickinson has repurchased $250 million worth of shares in 2026 and authorized an additional 10 million shares for buyback, indicating management's belief that the stock is undervalued and their dedication to enhancing shareholder value.
See More
Investment Opportunities in Becton, PepsiCo, and Procter & Gamble
- Becton’s Recovery Outlook: Following a spinoff, Becton, Dickinson's shares trade at approximately 12 times forward earnings, significantly lower than peers at 15 times, with analysts forecasting a rebound in earnings by 2027, which could drive stock price recovery and improve investor sentiment.
- PepsiCo's Undervalued Position: Despite facing potential impacts from GLP-1 weight-loss drugs and inflationary pressures, PepsiCo's stock currently trades at just 18 times forward earnings, compared to Coca-Cola's 23.5 times, indicating strong return potential while offering a 3.65% dividend yield.
- Procter & Gamble’s Steady Investment: With a 70-year track record of consecutive dividend growth, Procter & Gamble's stock trades near 20 times forward earnings, yet its average 6% annual dividend growth makes it an ideal choice for long-term wealth accumulation, especially during economic fluctuations.
- Market Opportunities and Risks: While the broader market may be recovering, high-quality dividend stocks still carry the risk of value traps, necessitating careful screening for companies with competitive advantages to avoid potential investment losses.
See More
